Theravance Biopharma TBPH Business Segments — Sales & Marketing
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's business segments — sales & marketing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's business segments — sales & marketing?
- Theravance Biopharma (TBPH) reported business segments — sales & marketing of $6.91M in Q1 2026.
- How has Theravance Biopharma's business segments — sales & marketing changed year-over-year?
- Theravance Biopharma's business segments — sales & marketing decreased by 5.4% year-over-year, from $7.31M to $6.91M.
- What is the long-term trend for Theravance Biopharma's business segments — sales & marketing?
- Over 2 years (2023 to 2025), Theravance Biopharma's business segments — sales & marketing has grown at a 18.6% compound annual growth rate (CAGR), from $21.2M to $29.82M.
- What does business segments — sales & marketing mean?
- This reflects the costs incurred to promote, distribute, and sell the company's pharmaceutical products to healthcare providers and markets. It indicates the level of investment in commercialization efforts to drive revenue growth.